SLC5A2 and diabetic kidney disease: Considering the improvement of renal prognosis by SGLT2 inhibition in DKD patients, the paradigm shift from “glomerulocentric” to “tubule centric” has emerged in the pathophysiology of DKD progression [8, 9].